Thursday, June 09, 2011

FDA Safety Announcement on Topamax and Pregnancy

In a safety announcement issued March 4, 2011, the Food and Drug Administration (FDA) released details of new human data studies for the prescription drug Topamax.

Topamax is a topiramate drug that is used, either alone or in combination with other drugs, in the treatment of epileptic seizures and to prevent migraine headaches. In the safety announcement the FDA stated that the drug, which had formerly been classified as a Pregnancy Category C drug, which had potential risk of birth defects when taken by pregnant women, was being reclassified as a Pregnancy Category D drug – one that has in human data shown to have positive evidence for risk to human fetuses during the first trimester of pregnancy.

If you were prescribed Topamax and have concerns that your child's birth defect might have been caused by the medication, personal injury lawyers O’Hanlon, McCollom & Demerath of Austin Texas would like to invite you to contact them for a consultation on if you might qualify to file a Topamax lawsuit for compensation to assist in paying the costly medical bills needed to treat your child's birth defect.

O’Hanlon, McCollom & Demerath
Personal Injury Lawyers
808 West Avenue
Austin, TX. 78701

phone: 512-494-9949

Note that in their safety announcement the FDA stated that there are cases where the risks of taking Topamax, and other topiramates, by pregnant women may be acceptable due to the specific benefits of the drug in the treatment of epileptic seizures.